Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pain, function, and acute neuropathic pain up to one month after surgery: a registry-based analysis.

Pain reports·2026
Same author

Correlation between mental health and pain-related impairment in patients with chronic cancer-related pain.

Frontiers in psychology·2026
Same author

Perioperative high-dose selenium supplementation in open thoracic aortic surgery: a post hoc subgroup analysis of the SUSTAIN CSX trial.

Journal of thoracic disease·2026
Same author

2025 ESAIC and ESPA Guidelines on neuromuscular block in anaesthetised children: Indications, monitoring and reversal.

European journal of anaesthesiology·2026
Same author

Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation (CRICKET)-study protocol for an international multicentre prospective observational study.

BJA open·2026
Same author

Partial cannabis legalization and the increase of the THC threshold in road traffic: a statistical analysis of traffic cases before and after legal changes.

Traffic injury prevention·2026
Same journal

Technical note: Development of a UHPLC-MS/MS method for the analysis of hCG and IGF-I from dried blood spots: A preliminary study.

Forensic science international·2026
Same journal

A novel and robust deep learning model for sibling firearm matching.

Forensic science international·2026
Same journal

Changes in C-reactive protein levels over time in high-temperature environments using postmortem blood.

Forensic science international·2026
Same journal

Insights from the first synthetic cannabinoid clandestine lab dismantled in Brazil.

Forensic science international·2026
Same journal

Determination of the new psychoactive substances MDMB-4en-PINACA, ADB-BUTINACA and some of their metabolites in blood and urine using DLLE-LC-MS/MS: application to real forensic case samples.

Forensic science international·2026
Same journal

The revolver halo as a forensic marker: Raman spectroscopic evidence of primer-driven gunshot residue deposition.

Forensic science international·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Pharmacogenetics in palliative care.

Maren Kleine-Brueggeney1, Frank Musshoff, Frank Stuber

  • 1Department of Anaesthesiology and Pain Therapy, Inselspital, University Hospital Bern, Freiburgstr., 3010 Bern, Switzerland. maren.kleine-brueggeney@insel.ch

Forensic Science International
|August 17, 2010
PubMed
Summary
This summary is machine-generated.

Individual drug response varies due to genetics. Research into pharmacogenetics, focusing on genetic variants like cytochrome P450 2D6, aims to personalize drug dosing for better patient outcomes.

Related Experiment Videos

Last Updated: Jun 10, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

  • Pharmacogenetics
  • Genomics
  • Drug Metabolism

Background:

  • Individual variability in response to analgesics, anticancer drugs, and other cancer-related pharmacotherapies is significant.
  • Factors like age, disease, comorbidities, and organ function contribute to this variability.
  • Research is increasingly focusing on genetic variations in drug-metabolizing enzymes to explain these differences.

Purpose of the Study:

  • To explore the role of genomic variants in drug metabolism, particularly phase I and II enzymes.
  • To discuss the influence of genetic polymorphisms on the efficacy and safety of key medications.
  • To highlight candidate genes beyond metabolizing enzymes relevant to pharmacotherapy.

Main Methods:

  • Review of existing literature on pharmacogenetics and drug metabolism.
  • Discussion of specific gene polymorphisms, such as cytochrome P450 2D6.
  • Identification of candidate genes including opioid receptors and transporters.

Main Results:

  • Polymorphisms in cytochrome P450 2D6 significantly affect the metabolism of analgesics (codeine, tramadol, hydrocodone, oxycodone), antidepressants, and tamoxifen.
  • Other genetic factors related to receptors and transporters are also implicated in pharmacotherapy.
  • Current evidence is often limited by small sample sizes and retrospective designs.

Conclusions:

  • Pharmacogenetics holds potential for individualizing drug dosage and improving patient therapy.
  • Further well-designed studies are required to validate the superiority of pharmacogenetics over conventional dosing.
  • Robust evidence is needed to establish pharmacogenetics as a standard clinical tool.